Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE2
10 participants
INTERVENTIONAL
2015-07-31
2016-03-03
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
A PET Brain Imaging Study of mGluR5 in Subjects With Neuropsychiatric Conditions
NCT00870974
Glutaminergic Transmission in Autism : Molecular Imaging Exploration
NCT02719951
Positron Emission Tomography (PET) to Study Brain Signaling
NCT00044200
Imaging Glutamate Release From Alcohol
NCT04159688
PET Imaging in ALS Patients
NCT02236897
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
NA
SINGLE_GROUP
DIAGNOSTIC
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
18F-PSS232
Subjects receive baseline PET with 18F-PSS232 and stimulation PET with 18F-PSS232 after medical challenge with N-acetylcystein
18F-PSS232
Diagnostic PET Tracer
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
18F-PSS232
Diagnostic PET Tracer
Other Intervention Names
Discover alternative or legacy names that may be used to describe the listed interventions across different sources.
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
Exclusion Criteria
* drug addiction
* significant neurological or psychiatric conditions
20 Years
75 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Zurich
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Alfred Buck, Prof. Dr.
Role: PRINCIPAL_INVESTIGATOR
University of Zurich
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University Hopsital Zurich
Zurich, , Switzerland
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
KEK ZH 2014-0441
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.